Navigation Links
Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
Date:5/20/2011

.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Our reliance on Acthar for substantially all of our net sales and profits;
  • Our ability to generate revenue from sales of Acthar to treat on-label indications associated with NS, and our ability to develop other therapeutic uses for Acthar;
  • Our ability to effectively manage our growth and our reliance on key personnel;
  • Volatility in Questcor's monthly and quarterly Acthar shipments
    '/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
2. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
3. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
4. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
5. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
6. Questcor Pharmaceuticals Selects BDO USA as its Auditor
7. Questcor Reports 2010 Financial Results
8. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
9. Questcor Pharmaceuticals Reports Strong Finish to 2010
10. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
11. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
(Date:12/24/2014)... SAN DIEGO , Dec. 24, 2014 /PRNewswire/ ... the West, developing the proprietary Natural Killer (NK) ... announces that Dr. Patrick Soon-Shiong , NantWorks ... into a definitive agreement to purchase approximately $48 ... In connection with the investment, he will be ...
(Date:12/24/2014)... and LONDON , December 24, ... industry are expected to grow at an average rate ... of value and volume. Hip, knee and spine surgeries ... while in emerging economies they have a lower penetration. ... challenging the use of composites. Non-metallic orthopedic devices have ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
(Date:12/24/2014)... Today, Yunx.co.uk, a hot style dress supplier that ... occasion outfits, unveils 65 new bridesmaid dresses ... prices, up to 80% off. , Yunx.co.uk’s dresses are ... designs, gorgeous looks and delicate craftsmanship. These new bridesmaid ... to designing and offering high-quality women’s dresses with fast ...
(Date:12/24/2014)... -- The holidays can be a challenge for people who ... and drinks. "This is the season in which many ... Dr. David Dodick, chair of the American Migraine Foundation, said ... to think through food and beverage choices, to help reduce ... professor of neurology at the Mayo Clinic in Scottsdale, Ariz. ...
(Date:12/24/2014)... By Tara Haelle ... (HealthDay News) -- Teens are more likely to start ... of attention-deficit hyperactivity disorder (ADHD) or conduct disorder, ... to counsel families about the risk of substance use ... William Brinkman, research director at Cincinnati Pediatric Research Group, ...
(Date:12/24/2014)... 2014 The Healthy Home Company has a ... families. In-Vest USA is dedicated to supporting ... our first responders. Today, these two organizations have joined forces ... them with body armor through In-Vest’s USA’s Bless the Vest ... happened this past week in New York. , ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Verde Pointe Dental ... than ever. "Last years homemade Christmas sweater lit up, ... The 2014 winner is Tandy Wilson for the second ... sweater enthusiast," says Kirk Kimmerling DDS. "She took pictures of ... on the sweater." , "Every year I enjoy ...
Breaking Medicine News(10 mins):Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:The Healthy Home Company and In-Vest USA Team Up to Save the Lives of Law Enforcement 2Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2
... developed by an immunologist Dr Brendan O'Sullivan of Brisbane, for ... skyrocketing rates// of medicines that is available for diabetes in ... UQ's Centre for Immunology and Cancer Research (CICR) are developing ... in obesity -- a common precursor to diabetes, reports foodconsumer.org. ...
... a million lives owing to treatment costs that very many ... Asia and Africa seem to be at the receiving end. ... coming out with a facility that would enable mass production ... capacity to lower the costs of each dose by 25 ...
... Major Pharmaceutical Company Roche launched its anti-cancer drug `Tarceva' ... patients//, suffering from lung cancer. ,The Managing Director ... tablet taken once a day and has the potential ... patients with locally advanced or metastatic Non-Small Cell Lung ...
... that the ?6.2bn upgrade of the NHS IT system ... magazine said that the group of academics are questioning if ... saying that the plan was under a "constant review" and ... 30,000 GPs in England to almost 300 hospitals by 2012. ...
... methods it ahs been found that survival rates following ... when emergency medical// personnel used a new form of ... Center. ,Cardiocerebral Resuscitation, is how this new approach is ... procedures. , ,In the words of Michael J. ...
... at assuming the role of a doctor but pretty bad ... University// of Technology has revealed that nearly half of all ... almost always higher than it should be. ,Over medication ... of overmedication have risen from 12% in 1987 to 33 ...
Cached Medicine News:Health News:Type 2 Diabetes Could Be Tackled Using Curry Colouring and Fat Mix 2Health News:Paramedics save more lives following unconventional rules 2
Fiber optic illumination with XHL xenon halogen illumination. Large-diameter glass viewing window with 3X magnification, airtight window seal and swivelling viewing window....
Designed for instrumentation under magnification. Both lens and speculum can be swivelled. Open construction to allow access and examination under magnification and illumination....
Cost-effective otoscope with xenon halogen illumination. Polycarbonate molded head. Acrylic viewing window with 3X magnification. Nasal and spreadable specula avaliable....
Provides 30% more illumination, high light output for true tissue. Wide-angle viewing lens, sealed system for pneumatic otoscopy....
Medicine Products: